Suppr超能文献

与经结膜玻璃体切除术相比,使用奥克纤溶酶进行药理玻璃体溶解术作为有症状的局灶性玻璃体黄斑牵引伴或不伴黄斑裂孔(≤400μm)的一种治疗选择

[Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].

作者信息

Maier M, Abraham S, Frank C, Lohmann C P, Feucht N

机构信息

Augenklinik, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr. 22, 81675, München, Deutschland.

出版信息

Ophthalmologe. 2017 Feb;114(2):148-154. doi: 10.1007/s00347-016-0322-9.

Abstract

BACKGROUND

To evaluate the resolution rate in patients with symptomatic vitreomacular traction (VMT) ≤ 1500 μm with or without macular holes ≤ 400 μm after therapy with intravitreal ocriplasmin (Jetrea®) injections in a clinical setting in comparison to transconjunctival vitrectomy.

MATERIALS AND METHODS

We examined 21 eyes of 21 consecutive patients with vitreomacular traction with or without macular holes who underwent intravitreal injection of 0.1 ml ocriplasmin and we retrospectively reviewed 18 eyes of 18 patients with VMT with or without FTMH who underwent 23-gauge vitrectomy.

RESULTS

Vitreomacular traction resolved in 15 of 21 eyes treated with ocriplasmin after 6 month (71 %) compared to 100 % of eyes treated by vitrectomy. Of the 5 eyes that initially presented FTMH with VMT in the ocriplasmin group, 2 were closed 1 month after ocriplasmin treatment. The remaining 3 had vitrectomy and closed thereafter. Best corrected visual acuity was 0.38 ± 0.23 LogMAR at baseline, improving to 0.34 ± 0.24 LogMAR at 6 months after ocriplasmin treatment. Best corrected visual acuity in the vitrectomy group improved from 0.55 ± 0.29 LogMAR before operation to 0.53 ± 0.51 LogMAR 6 months postoperatively. Foveal thickness was 355.95 ± 114.53 μm at baseline, reducing to 277.77 ± 40.26 μm at 6 months after ocriplasmin treatment. Foveal thickness of eyes that underwent vitrectomy was 494.61 ± 126.02 μm at baseline, decreasing to 330.2 ± 88.85 μm 6 months postoperatively.

CONCLUSION

When traction is ≤ 1500 μm, enzymatic vitreolysis with ocriplasmin is a therapeutic option. In the presence of VMT >1500 μm or ERM, surgical treatment with vitrectomy is associated with better outcomes. In small macular holes with VMT and in the absence of ERM, enzymatic vitreolysis with ocriplasmin is an option. In cases of holes >400 μm, or in the absence of evident VMT, or in the presence of ERM, vitrectomy is the first choice.

摘要

背景

在临床环境中,评估玻璃体内注射奥克纤溶酶(Jetrea®)治疗有或无直径≤400μm黄斑裂孔的症状性玻璃体黄斑牵拉(VMT)≤1500μm患者的缓解率,并与经结膜玻璃体切除术进行比较。

材料与方法

我们检查了21例连续的有或无黄斑裂孔的玻璃体黄斑牵拉患者的21只眼,这些患者接受了0.1ml奥克纤溶酶玻璃体内注射,并且我们回顾性分析了18例有或无特发性全层黄斑裂孔(FTMH)的VMT患者的18只眼,这些患者接受了23G玻璃体切除术。

结果

奥克纤溶酶治疗的21只眼中有15只(71%)在6个月后玻璃体黄斑牵拉得到缓解,而玻璃体切除术治疗的眼缓解率为100%。在奥克纤溶酶组最初表现为伴有VMT的FTMH的5只眼中,2只在奥克纤溶酶治疗1个月后裂孔闭合。其余3只眼接受了玻璃体切除术,此后裂孔闭合。最佳矫正视力在基线时为0.38±0.23 LogMAR,在奥克纤溶酶治疗6个月后提高到0.34±0.24 LogMAR。玻璃体切除术组的最佳矫正视力从术前的0.55±0.29 LogMAR提高到术后6个月的0.53±0.51 LogMAR。中心凹厚度在基线时为355.95±114.53μm,在奥克纤溶酶治疗6个月后降至277.77±40.26μm。接受玻璃体切除术的眼中心凹厚度在基线时为494.61±126.02μm,术后6个月降至330.2±88.85μm。

结论

当牵拉≤1500μm时,奥克纤溶酶酶解玻璃体是一种治疗选择。当VMT>1500μm或存在视网膜前膜(ERM)时,玻璃体切除术的手术治疗效果更好。对于伴有VMT的小黄斑裂孔且无ERM时,奥克纤溶酶酶解玻璃体是一种选择。对于直径>400μm的裂孔,或无明显VMT,或存在ERM的情况,玻璃体切除术是首选。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验